Clinical trialNCT04631211TerminatedPhase 2Interventional

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

SponsorCellphire Therapeutics, Inc.Enrollment21Bone Marrow AplasiaHematologic MalignancyMyelodysplastic SyndromesMyeloproliferative DisordersPlatelet RefractorinessThrombocytopenia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate, in a dose-escalation manner, the safety, and impact on bleeding, and the preliminary effect on coagulation measures of increasing doses of allogeneic Thrombosomes in comparison to standard of care, LSP.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mike Fitzpatrick, PhD
Cellphire Therapeutics, Inc.
Study Director
clinicaltrials.gov ↗
Terry Gernsheimer, MD
University of Washington
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Israel

Rambam Medical Center
Haifa, Israel

Norway

Helse Bergen Haukeland University Hospital
Bergen, Norway

United States

City of Hope
Duarte, California, United States
Medstar Georgetown
Washington D.C., District of Columbia, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Liquid Stored PlateletsThrombosomes

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Mar 2021
Primary completion: 7 Jan 2022
Completion: 7 Jan 2022
Last update posted: 25 May 2023
Registered enrollment: 21
Registry id: NCT04631211

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.